Interleukins (IL)-4 and-13 play a pivotal role in the pathobiology of type-2 asthma. Indeed, IL-
4 is crucially involved in Th2 cell differentiation, immunoglobulin (Ig) class switching and …

Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

Background The efficacy of dupilumab as biological treatment of severe asthma and chronic
rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Chronic lung diseases are the third leading cause of death worldwide and are increasing in
prevalence over time. Although much of our traditional understanding of health and disease …

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking …

Background Having been approved for biological treatment of atopic dermatitis, dupilumab
has also been recently licensed as add-on therapy for severe asthma and nasal polyposis …

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory
condition of nasal mucosa and paranasal sinuses, predominantly mediated by type 2 …

Advances in the understanding that severe asthma is a complex and heterogeneous
disease and in the knowledge of the pathophysiology of asthma, with the identification of …

Allergic asthma has traditionally been treated with inhaled and systemic
glucocorticosteroids. A continuum of allergic fungal airways disease associated with …